Vasogenix Pharmaceuticals

VasoGenix Video Coming Soon.
Please check back soon.

VasoGenix Pharmaceuticals, Inc. is developing intravenous and controlled release drug (CRD) treatments for addressing Heart Failure and other cardiac diseases in order to reduce the recurrence of these diseases and their resulting hospital and medical costs.

At VasoGenix we are not satisfied just treating the symptoms of heart failure. Our goal is to slow the progression, decrease hospital stays and readmissions. To do so requires a special drug with unique with properties. It requires the perfect drug for the heart.

Company Information (PPS)
About VasoGenix

VasoGenix Video (12 minutes)

Recent News

05/10/2010
VasoGenix to Present VSXP325 at 2010 Heart Failure Society Meeting
The Company was selected to present recent data on it's new drug candidate VSXP325. The presentation titled: Calcitonin Gene Related Peptide (CGRP) Analog VSXP325 as a Bridging Therapy in Heart Failure, will be presented by Asad Sheikh from The University of Kansas Hospital and Medical Center Kansas City.
02/12/2010
Developing Attack Against U.S. Number One Killer
In conjunction with National Heart Failure Awareness Week, VasoGenix, a Lenexa-based pharmaceutical company, announces major progress on its upcoming new drug to reduce and treat heart failure.
05/19/2009
VasoGenix Pharmaceuticals elects Cleveland Clinic’s James Young, M.D., to its board of directors
LENEXA, Kan., May 19, 2009—VasoGenix Pharmaceuticals announced today that heart failure/heart transplant cardiologist James Young, M.D., has been elected to its board of directors.